Kenvue (KVUE) Q3 2026 earnings review
Kenvue medicine sales rebound, but its skin care recovery stalls
Kenvue, the maker of Tylenol and Neutrogena, grew revenue faster as medicine demand recovered, while its skin-care turnaround stalled. Sales from businesses owned a year ago rose 3%, helped by Asian distributor restocking and higher gross margins from US tariff refunds. Chief executive Kirk Perry said the business transformation remains on track as the Kimberly-Clark buyout nears completion, though by our math two-year underlying sales are still down 1.5%.
| Sales from businesses owned a year ago | +2.9% -4.4% a year ago |
|---|---|
| Skin Health underlying sales | -0.5% +3.7% last quarter |
| Profit per share, excluding one-offs | $0.29 +4% from a year ago |
| Full-year financial outlook | Suspended $250M restructuring plan unchanged |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because a medicine rebound and a skin-care setback cancelled each other out. Self Care shipment volumes grew again and Essential Health profit recovered, but Skin Health and Beauty shrank on lost US shelf space and European retailer pushback despite an easy comparison.
The question now is whether Kenvue's sales recovery reflects genuine shopper demand or just an easy comparison against last year's slump. Either new products are winning back customers, or restocking and weak prior-year baselines are masking flat US demand. Fourth-quarter shipment volumes against a positive prior-year comparison will tell.
🐂 Bull Case
Self Care Volume Rebounded on Asian Restocking
Self Care is Kenvue's largest division, selling over-the-counter medicines such as Tylenol, Motrin and Nicorette. Weak cold and flu seasons hurt the unit's volume during the first half of the year, when shipments fell 2.3%.
That drop reversed this quarter. Sales from businesses owned a year ago rose 5.4%, as shipment volume climbed 3.4% and prices and product mix added 2.0%. Kenvue said Motrin beat the broader pain-relief market during rising flu cases in Asia, while Nicorette smoking-cessation products grew by a low double-digit percentage.
The rebound eases a standing concern over medicine demand, but part of the gain came from an easy comparison. Kenvue noted that Asian results benefited from "favorable inventory-related comparisons following prior year trade inventory depletion" rather than pure shopper demand.
What to watch: Self Care shipment volume in the fourth quarter. A second quarter of volume growth against a tougher prior-year comparison would show that consumer demand is holding up without restocking help.
Tariff Refunds and Supply Savings Lifted Gross Margin
Higher input costs and tariffs squeezed profitability last quarter, pulling gross margin down by 0.7 percentage points. Kenvue has been running supply-chain and restructuring programmes to offset those pressures and pay for extra advertising.
Those efforts paid off in the third quarter. Cost of sales — the cost of making Kenvue's products — fell by 0.4 percentage points of revenue by our math, lifting gross margin to 59.5% from 59.1% a year ago. Management credited supply-chain efficiency, higher prices and "U.S. tariff refunds" for the improvement.
Operating margin rose 1.5 percentage points to 18.2%. Restructuring expenses dropped by 1.4 percentage points of revenue by our math, while overhead savings covered a 0.2-point rise in selling, general and administrative expenses from higher brand advertising. Because tariff refunds do not repeat every quarter, part of the gross margin gain is one-off.
What to watch: the quarterly filing's breakdown of the tariff refund size. A small refund would mean supply-chain savings did most of the work and can keep lifting margins.
Essential Health Profit Grew Again as Volume Rose
Essential Health sells everyday staples including Listerine mouthwash, Band-Aid bandages and Johnson's Baby products. In the second quarter, price cuts and heavy marketing pushed the division's operating profit excluding one-offs down 10.3%, raising concern that Kenvue had to sacrifice profit to defend its shelf space.
The unit stabilised this quarter. Sales from businesses owned a year ago grew 2.5%, led by a 2.0% rise in shipment volume and a 0.5% gain from prices and product mix. Segment operating profit excluding one-offs rose 2.6% by our math to $315 million, up from $307 million a year ago, as new launches like Stayfree pads in India and Band-Aid Pro Heal bandages brought in buyers without requiring net price cuts.
What to watch: Essential Health prices and product mix in the fourth quarter. A second positive reading would show that the first-half price cuts were temporary promotions rather than a permanent reset.
🐻 Bear Case
Skin Health Recovery Stalled on Lost Shelf Space
Skin Health and Beauty — home to Neutrogena skin care, Aveeno and OGX hair products — was supposed to be the main engine of Kenvue's turnaround. After growing underlying sales by 5.0% in the first quarter and 3.7% in the second, the division carried low goodwill headroom on the balance sheet and needed steady gains to prove its recovery.
Instead, the rebound broke down against an easy prior-year comparison of minus 3.5%. Sales from businesses owned a year ago fell 0.5% as shipment volume dropped 1.7%, outweighing a 1.2% lift from prices and product mix. Kenvue blamed the drop on "distribution losses and timing of promotions in the U.S. and the impact of retailer negotiations in Europe".
Losing retail distribution in the US and fighting over terms with European grocers shows that Neutrogena and its sister brands still struggle for shelf space, even while Rogaine hair care grew by a low double-digit percentage.
What to watch: Skin Health and Beauty shipment volume in the fourth quarter, when the prior-year comparison toughens to plus 1.5%. Another volume drop would increase the risk of a goodwill write-down.
Easy Comparisons Flattered the Third-Quarter Rebound
"We are strongly on track to deliver our business transformation that we began last year," chief executive Kirk Perry said, pointing to a fourth straight quarter of revenue growth. Headline sales rose 3.2% to $3.89 billion, and sales from businesses owned a year ago grew 2.9%.
- Third-quarter underlying sales: up 2.9%, lapping a 4.4% drop in the third quarter of 2025
- Two-year underlying sales change: down 1.5% by our math
- North America reported net sales: $1,761 million, down 0.2% from $1,765 million a year ago by our math
Those figures cut against Perry's transformation claim because the acceleration came from lapping last year's slump rather than expanding past prior levels. North America, which brings in 45% of Kenvue's revenue, still shrank slightly as US shoppers bought less skin care and seasonal illness stayed mild.
What to watch: fourth-quarter underlying sales growth, which laps a positive 1.2% base from late 2025. Holding growth above zero against a positive comparison would show that the recovery stands on its own.
Risks this quarter didn't answer
Because Kenvue is being acquired by Kimberly-Clark, management held no conference call and left three standing risks unaddressed in the earnings release.
- Tylenol and phenylephrine lawsuits: the release gave no update on the autism and decongestant cases revived by a US appeals court in July; the quarterly 10-Q filing's legal footnote will carry any schedule changes.
- Merger closing approvals: management repeated that the Kimberly-Clark deal is nearing completion, but named no remaining foreign regulatory approvals or closing date.
- Mouthwash market share: the release highlighted Listerine pocket packets, but gave no figures on whether Kenvue stopped losing share to rival alcohol-free mouthwashes.
👓 Other Themes
Higher Tax Rate Held Back Net Income Growth
Last quarter, a tax allowance release lowered Kenvue's tax bill and lifted net income growth far above operating profit growth. In the third quarter, that tailwind reversed: the effective tax rate rose to 29.4% from 24.3% a year ago because of fewer favourable tax-return adjustments. As a result, operating profit jumped 12.2% to $706 million, while net income grew 8.0% by our math to $430 million.
💲 Other KPIs
Free cash flow — operating cash left after capital spending on factories and equipment — rose 60% by our math over the first nine months, up from $1.0 billion a year ago. Higher net income, smaller working-capital needs and a $100 million reduction in capital spending drove the gain. By our math, third-quarter free cash flow reached $600 million.
Net debt — total borrowings minus cash on hand — fell by $300 million from $7.5 billion at the end of December 2025. Total debt declined from $8.5 billion to $8.2 billion over the nine-month period as stronger operating cash flow covered dividend payments and debt reduction, while cash on hand edged down from $1.1 billion to $1.0 billion.
Combined net sales in Latin America and Asia Pacific rose 11.1% by our math from $1,040 million a year ago, carrying Kenvue's top line while North America stagnated. Latin America jumped 12.5% to $414 million on baby care launches, and Asia Pacific grew 10.3% to $741 million on flu-medicine demand and restocking.
🔮 Guidance
Unchanged. Kenvue still expects about $250 million in pre-tax restructuring and operating-model charges this year under the programme it approved in February to "optimize its operating model, transform its supply chain, reduce complexity, and drive operational efficiencies". With $188 million spent in the first nine months ($41 million in Q3), by our math that leaves about $62 million of charges for the fourth quarter.
❓ Key Questions
Which foreign regulators still need to approve the Kimberly-Clark deal?
Management said Kenvue is nearing the completion of its combination with Kimberly-Clark, which was previously slated to close in late 2026. The release did not state which international antitrust or regulatory sign-offs remain open.
How large were the US tariff refunds in Q3?
Gross margin rose 0.4 percentage points in part because of US tariff refunds. Investors need the dollar amount to separate one-time duty recoveries from ongoing supply-chain savings.
How much US shelf space did Skin Health lose?
Skin Health and Beauty volume fell 1.7% on US distribution losses and European retailer talks. Management has not said whether those lost retail slots are permanent for the upcoming year.
What is the schedule for the revived Tylenol lawsuits?
After a US appeals court revived the acetaminophen and phenylephrine lawsuits in July, the earnings release gave no legal update. The upcoming 10-Q filing must clarify the court timeline.